Combination Strategies A Common Thread In NASH R&D
Executive Summary
Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.
You may also be interested in...
Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH
Metacrine halts development of its FXR agonist compounds in NASH and turn its focus to inflammatory bowel disease. Firm plans Phase II ulcerative colitis study in 2022 with MET642.
Gilead Increasingly Seems Focused On Combo Therapy In NASH
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.
Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of a trial in portal hypertension.